X

Trial Profile

Phase I/II double blinded, placebo-controlled study of Zofin™ for patients suffering with knee osteoarthritis

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zofin (Primary)
Indications Osteoarthritis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Mar 2024 According to a ZEO ScientifiX, Inc media release, company name changed from Organicell to ZEO ScientifiX.
22 Apr 2021 New trial record
21 Apr 2021 According to an Organicell media release, the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for Zofin in the treatment of knee osteoarthritis and the study is expected to start in the second quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com